Grail's Cancer Blood Test Faces High-Stakes FDA Review

FDA Panel Recommends Approval Of GRAIL's Galleri Multi-Cancer Early Detection Test

GRAIL Inc.'s (GRAL) Galleri multi-cancer early detection test has received a favorable vote from the FDA panel, making it one step closer to approval. The FDA's final decision on Galleri is expected in the coming months. The U. S. regulator usually follows the recommendations of its panels, although it is not mandatory to do so.

GRAIL's Galleri test wins endorsement from FDA panel (NASDAQ:GRAL)

A panel of US FDA advisors voted that there is reasonable evidence that GRAIL’s (GRAL) multi-cancer early detection blood test Galleri is effective. The vote wa

FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical…

This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.

FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks

The screening test holds the promise of detecting cancer early, when tumors can be treated more effectively. But there are also risks.

Galleri, The Blood Test That Can Detect Cancers, Is Up For FDA Approval Today

Multi-Cancer Early Detection (MCED) testing is a rapidly growing field.